Sign Out
The concentration of the albumin preparation, dosage and the infusion-rate must be adjusted to the patient's individual requirements.
The dose required depends on the size of the patient, the severity of trauma or illness and on continuing fluid and protein losses. Measures of adequacy of circulating volume and not plasma albumin levels must be used to determine the dose required.
If human albumin is to be administered, haemodynamic performance must be monitored regularly. This may include: arterial blood pressure and pulse rate; central venous pressure; pulmonary artery wedge pressure; urine output; electrolyte; haematocrit/haemoglobin.
Paediatric population: The safety and efficacy of UMAN ALBUMIN in children have not been established by controlled clinical trials and its use in paediatric population is based only on established medical practice. For this reason, UMAN ALBUMIN must be used in children only if clearly necessary. UMAN ALBUMIN can be administered to premature infants.
Patients with renal impairment: UMAN ALBUMIN can be administered to dialysis patients as the aluminium content of the finished product is not more than 200 μg/l.
Method of administration: Human albumin can be directly administered by the intravenous route, or it can also be diluted in an isotonic solution (e.g. 5% glucose or 0.9% sodium chloride).
The infusion rate must be adjusted according to the individual circumstances and the indication. In Plasma exchange the infusion-rate must be adjusted to the rate of removal.
